Kazia Therapeutics Ltd ADR (KZIA)

$5.34 +0.33 (6.59%)
Market Cap 8.28M
Revenue (ttm) 1.23M
Net Income (ttm) -13.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,090.24%
Debt to Equity Ratio -0.05
Volume 136,400
Avg Vol 231,928
Day's Range N/A - N/A
Shares Out 1.65M
Stochastic %K 35%
Beta 1.77
Analysts Strong Sell
Price Target $19.00

Company Profile

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphom...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 9472 4101
Address:
Three International Towers, Level 24 300 Barangaroo Avenue, Sydney, Australia
MisterBean26
MisterBean26 Feb. 18 at 1:22 AM
$KZIA trading 212 in the UK just unlocked more shares to buy. Tactical? Or a trap? I believe it's tactical. News is coming 🤞🏻
0 · Reply
Longbuy1
Longbuy1 Feb. 15 at 6:20 PM
$KZIA At low, wouldn't be surprised to see a run to 14$
0 · Reply
gaboriar
gaboriar Feb. 15 at 2:56 PM
$AKBA $KZIA clockwork
0 · Reply
gaboriar
gaboriar Feb. 15 at 2:55 PM
$KZIA this stock is hilarious. Best set it and forget it medium term flipper ever.
0 · Reply
_MihawkSwings
_MihawkSwings Feb. 15 at 7:36 AM
OLB 💎 What a close! Next week is going to be big here. Make sure to keep OLB on ur watch if you haven't added. Upcoming catalyst- DMINT spint off . ✅ Pennies have been hot and I believe we continue the trend into next week as well. OLB has the look and Setup to see a parabolic move from here on. . $1+ potential.. ​. $CBUS $POAI $KZIA $SUGP watching.
1 · Reply
futureexmillionare
futureexmillionare Feb. 14 at 3:01 AM
$KZIA 👉 Feb–Apr 2026: FDA meeting result 👉 Spring 2026: More TNBC data 👉 Mid 2026: IND filing or partner 👉 Late 2026: Phase 3 plan news Thats chat GPT prediction positive FDA meeting $10-$20 ⭐ Scenario 3 — GBM + TNBC + NDL2 Platform NDL2 is a PD-L1 degrader platform. Platforms can be extremely valuable if early data looks strong. Even preclinical platform can add: 👉 $200M–$800M option value. Math GBM = $1B TNBC = $300M NDL2 = $300M 👉 $1.5B–$2.5B total This is how small biotechs get big buyouts. 👍 My Honest Opinion If FDA meeting says: 👉 “Accelerated approval path possible” Then $1B+ buyout becomes realistic very fast. Without that, buyers wait.
0 · Reply
topstockalerts
topstockalerts Feb. 14 at 1:18 AM
After Hours Top Gainers PT2 $FRGT $KZIA $GLXG $OLB $PPCB
0 · Reply
1Kiongozi
1Kiongozi Feb. 14 at 12:46 AM
*hey guys ticker IBG could set up for a massive squeeze next week. *SMX ran on 1 mil float IBG has 580k float, put IBG on your watchlist. IBG next week big squeeze watch merger news took a big position. $NCI $FRGT $ATGL $KZIA <<<>>>
0 · Reply
VoidGorilla
VoidGorilla Feb. 13 at 11:01 PM
-hey guys ticker IBG could set up for a massive squeeze next week. SMX ran on 1 mil float IBG has 580k float, put IBG on your watchlist. IBG next week big squeeze watch merger news took a big position}{ $KZIA $RMSG $LFS $CTW <<< on watch.
0 · Reply
10baggerPete
10baggerPete Feb. 13 at 7:08 PM
$KZIA patience grasshopper!
0 · Reply
Latest News on KZIA
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Jan 30, 2026, 8:00 AM EST - 18 days ago

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Jan 27, 2026, 8:00 AM EST - 21 days ago

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Jan 8, 2026, 9:00 AM EST - 5 weeks ago

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Dec 22, 2025, 8:00 AM EST - 2 months ago

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

Dec 10, 2025, 8:00 AM EST - 2 months ago

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

What's Going On With Cancer Firm Kazia Therapeutics

Dec 2, 2025, 12:21 PM EST - 2 months ago

What's Going On With Cancer Firm Kazia Therapeutics

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

Dec 2, 2025, 9:00 AM EST - 2 months ago

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Nov 18, 2025, 4:15 PM EST - 3 months ago

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

Oct 27, 2025, 7:15 AM EDT - 4 months ago

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

Oct 7, 2025, 8:30 AM EDT - 4 months ago

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen

Oct 2, 2025, 8:30 AM EDT - 4 months ago

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen

Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG

Oct 1, 2025, 9:21 AM EDT - 4 months ago

Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

Sep 11, 2025, 8:00 AM EDT - 5 months ago

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

Aug 1, 2025, 8:00 AM EDT - 7 months ago

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

Jul 9, 2025, 8:00 AM EDT - 7 months ago

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

Jun 11, 2025, 8:00 AM EDT - 8 months ago

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Jun 5, 2025, 8:00 AM EDT - 9 months ago

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Highlights Recent Progress and Provides Business Update

May 15, 2025, 8:00 AM EDT - 9 months ago

Kazia Therapeutics Highlights Recent Progress and Provides Business Update

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

Mar 31, 2025, 7:30 AM EDT - 11 months ago

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Jan 30, 2025, 7:30 AM EST - 1 year ago

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Jan 14, 2025, 4:00 PM EST - 1 year ago

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Jan 10, 2025, 9:58 AM EST - 1 year ago

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

Dec 31, 2024, 12:34 PM EST - 1 year ago

Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Dec 31, 2024, 8:00 AM EST - 1 year ago

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Dec 11, 2024, 8:00 AM EST - 1 year ago

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Nov 4, 2024, 7:30 AM EST - 1 year ago

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Oct 2, 2024, 8:45 AM EDT - 1 year ago

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

Sep 23, 2024, 8:30 AM EDT - 1 year ago

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Sep 12, 2024, 7:30 AM EDT - 1 year ago

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment

Jul 10, 2024, 12:24 PM EDT - 1 year ago

Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

Jun 27, 2024, 8:15 AM EDT - 1 year ago

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

May 23, 2024, 2:41 PM EDT - 1 year ago

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

May 1, 2024, 8:45 AM EDT - 1 year ago

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Mar 21, 2024, 8:52 AM EDT - 2 years ago

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Kazia announces presentation of new data at AACR Annual Meeting

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Kazia announces presentation of new data at AACR Annual Meeting

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Feb 21, 2024, 7:30 AM EST - 2 years ago

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Jan 18, 2024, 7:30 AM EST - 2 years ago

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

Dec 5, 2023, 6:02 PM EST - 2 years ago

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

Kazia Therapeutics Announces $2 Million Registered Direct Offering

Dec 1, 2023, 8:00 AM EST - 2 years ago

Kazia Therapeutics Announces $2 Million Registered Direct Offering

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

Nov 29, 2023, 7:01 AM EST - 2 years ago

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Nov 21, 2023, 7:30 AM EST - 2 years ago

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

Nov 20, 2023, 4:30 PM EST - 2 years ago

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Nov 15, 2023, 8:30 AM EST - 2 years ago

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA

Nov 10, 2023, 7:01 AM EST - 2 years ago

KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA

KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA

Nov 1, 2023, 7:01 AM EDT - 2 years ago

KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA

KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY

Oct 23, 2023, 7:01 AM EDT - 2 years ago

KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY

Kazia announces voluntary delisting from ASX

Oct 11, 2023, 7:01 AM EDT - 2 years ago

Kazia announces voluntary delisting from ASX

KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS

Oct 5, 2023, 7:01 AM EDT - 2 years ago

KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS

KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

Sep 29, 2023, 7:01 AM EDT - 2 years ago

KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

MisterBean26
MisterBean26 Feb. 18 at 1:22 AM
$KZIA trading 212 in the UK just unlocked more shares to buy. Tactical? Or a trap? I believe it's tactical. News is coming 🤞🏻
0 · Reply
Longbuy1
Longbuy1 Feb. 15 at 6:20 PM
$KZIA At low, wouldn't be surprised to see a run to 14$
0 · Reply
gaboriar
gaboriar Feb. 15 at 2:56 PM
$AKBA $KZIA clockwork
0 · Reply
gaboriar
gaboriar Feb. 15 at 2:55 PM
$KZIA this stock is hilarious. Best set it and forget it medium term flipper ever.
0 · Reply
_MihawkSwings
_MihawkSwings Feb. 15 at 7:36 AM
OLB 💎 What a close! Next week is going to be big here. Make sure to keep OLB on ur watch if you haven't added. Upcoming catalyst- DMINT spint off . ✅ Pennies have been hot and I believe we continue the trend into next week as well. OLB has the look and Setup to see a parabolic move from here on. . $1+ potential.. ​. $CBUS $POAI $KZIA $SUGP watching.
1 · Reply
futureexmillionare
futureexmillionare Feb. 14 at 3:01 AM
$KZIA 👉 Feb–Apr 2026: FDA meeting result 👉 Spring 2026: More TNBC data 👉 Mid 2026: IND filing or partner 👉 Late 2026: Phase 3 plan news Thats chat GPT prediction positive FDA meeting $10-$20 ⭐ Scenario 3 — GBM + TNBC + NDL2 Platform NDL2 is a PD-L1 degrader platform. Platforms can be extremely valuable if early data looks strong. Even preclinical platform can add: 👉 $200M–$800M option value. Math GBM = $1B TNBC = $300M NDL2 = $300M 👉 $1.5B–$2.5B total This is how small biotechs get big buyouts. 👍 My Honest Opinion If FDA meeting says: 👉 “Accelerated approval path possible” Then $1B+ buyout becomes realistic very fast. Without that, buyers wait.
0 · Reply
topstockalerts
topstockalerts Feb. 14 at 1:18 AM
After Hours Top Gainers PT2 $FRGT $KZIA $GLXG $OLB $PPCB
0 · Reply
1Kiongozi
1Kiongozi Feb. 14 at 12:46 AM
*hey guys ticker IBG could set up for a massive squeeze next week. *SMX ran on 1 mil float IBG has 580k float, put IBG on your watchlist. IBG next week big squeeze watch merger news took a big position. $NCI $FRGT $ATGL $KZIA <<<>>>
0 · Reply
VoidGorilla
VoidGorilla Feb. 13 at 11:01 PM
-hey guys ticker IBG could set up for a massive squeeze next week. SMX ran on 1 mil float IBG has 580k float, put IBG on your watchlist. IBG next week big squeeze watch merger news took a big position}{ $KZIA $RMSG $LFS $CTW <<< on watch.
0 · Reply
10baggerPete
10baggerPete Feb. 13 at 7:08 PM
$KZIA patience grasshopper!
0 · Reply
Bio_Be_Dirty
Bio_Be_Dirty Feb. 13 at 6:57 PM
$KZIA monster ride coming
0 · Reply
PT3
PT3 Feb. 13 at 6:41 PM
$KZIA bought more
0 · Reply
ocellated
ocellated Feb. 13 at 2:35 PM
$KZIA October 27, 2025 PR Newswire - "Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS) findings in newly diagnosed glioblastoma (GBM) patients treated with paxalisib and to seek agency feedback on a potential regulatory pathway aligned with the FDA Oncology Center of Excellence's Project FrontRunner initiative." Is this no longer a thing?
2 · Reply
Rinnekin
Rinnekin Feb. 13 at 11:14 AM
$KZIA https://clinicaltrials.gov/study/NCT07391215?intr=Paxalisib&rank=3&tab=study Another collaborative study in GBM has started recruitment. This one appears to be more biomarker driven than GBM AGILE. It will be interesting to see if patients included here will be considered in the upcoming FDA discussion.
0 · Reply
NYC95Greg
NYC95Greg Feb. 12 at 6:22 PM
$KZIA a bit more color… -if they get to 5 or 6 patients with responses, the stock can potentially reach $25-$35. -New data that shows the drug works in HER2 breast cancer and would alert people that KZIA is a comp to CELC ($4.8b mkt cap). -Further, KZIA’s degrader program could easily be monetized (partner). They bought it on the cheap and a comp gets a huge multiple for something less than what KZIA has. -CEO is a very bright and hard working guy. He will hire additional management soon. -Risk/reward is off the charts here.
5 · Reply
Longbuy1
Longbuy1 Feb. 12 at 4:08 PM
$KZIA there's no volume, real price once it moves at all is still 6+
1 · Reply
Dollar_1
Dollar_1 Feb. 12 at 3:57 PM
$KZIA is this mother of all scams or what?
1 · Reply
futureexmillionare
futureexmillionare Feb. 12 at 3:47 PM
$KZIA Now you can buy at $5 .. dont complain later that you should have. Be a long time investor just like big boys.
0 · Reply
10baggerPete
10baggerPete Feb. 12 at 3:29 PM
$KZIA So that's an absolute Super duper double bottom @ $5 Now it can go moon
0 · Reply
GABBYGIRL
GABBYGIRL Feb. 12 at 12:35 PM
$KZIA agreed!
0 · Reply
Buy_Low
Buy_Low Feb. 11 at 4:03 PM
$KZIA https://www.marketscreener.com/news/kazia-therapeutics-annual-report-2025-ce7e5adcd180ff24
0 · Reply
NYC95Greg
NYC95Greg Feb. 11 at 3:30 PM
$KZIA Buying KZIA here. Multiple exciting initiatives (not a 1 trick pony). -Multiple data releases throughout the year. By summer, it should show more solid opportunity… -Has 2 years cash (excluding Phase 3 cash) -May get Analyst coverage.
1 · Reply